Ascelia Pharma Q2 2026 slides: FDA meeting key after Orviglance setback
Ascelia Pharma reported its Q2 2026 results on August 20, 2026, following a regulatory setback for its lead drug Orviglance. The company's shares dropped to $0.59, near the bottom of their 52-week range. The upcoming FDA meeting on September 9, 2026, was seen as crucial for determining Orviglance's regulatory path after a Complete Response Letter (CRL) was issued in early July.
The CRL raised concerns about clinical and product quality aspects of Orviglance. Ascelia Pharma argued that the FDA's clinical concerns, such as re-reading images and potential bias, could affect the reliability of primary results. The company's rebuttal focused on systematic bias in the original image evaluation. Ascelia reported a SEK 12 million operating loss in Q2 2026, an improvement from SEK 23 million in the same period of 2025.
The company's liquidity position, as of June 30, 2026, stood at SEK 38 million, supported by a share issue. Despite the setback, Ascelia maintained that Orviglance's commercial opportunity remains compelling, with an estimated global market of $800 million. The company also highlighted progress in its Oncoral project, an oral irinotecan formulation with a unique metronomic dosing approach.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
